<DOC>
	<DOCNO>NCT03045848</DOCNO>
	<brief_summary>LEADERS-FREE trial demonstrate safety efficacy polymer-free drug-coated stent ( Biofreedom , Biosensors International Technologies , Singapore ) patient high bleed risk . But , limited clinical evidence extend finding generalize patient eligible PCI . Therefore , purpose registry evaluate safety efficacy Biofreedom stent patient coronary artery disease .</brief_summary>
	<brief_title>Biofreedom Prospective Multicenter Observational Registry</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) relate interventional cardiology field rapidly grow current era . First generation drug elute stent ( DES ) need long-term dual antiplatelet therapy ( DAPT ) prevent future stent thrombosis . But , second generation DES show well clinical outcome term target lesion revascularization stent thrombosis . Later , polymer technology use release drug gradually improve . BASKET-PROVE II trial compare biodegradable polymer ( BP ) DES ( Nobori , Terumo ) durable polymer DES ( Xience Prime , Abbott Vascular ) bare metal stent ( ProKinetik , Biotronik ) safety efficacy 2-year follow-up . BP-DES show 7.6 % event rate composite endpoint include cardiac death , myocardial infarction ( MI ) , clinically indicate target-vessel revascularization ( TVR ) non-inferior DP-DES ( 6.8 % ) superior bare metal stent ( 12.7 % ) . There statistical difference event rate stent thrombosis , MI cardiac death among three group 1-year follow-up . Biodegradable polymer begin emerge suggest possibility shorten duration DAPT . LEEDERS-FREE trial design confirm safety efficacy polymer-free drug-coated stent ( Biofreedom , Biosensors International Technologies , Singapore ) compare bare metal stent ( Gazelle stent , Biosensors International Technologies , Singapore ) patient high bleed risk . During 390 day , drug coat stent show significant superiority bare metal stent safety composite endpoint ( cardiac death , MI stent thrombosis ) ( 9.4 % vs. 12.9 % , P=0.0005 ) . Clinically-driven target-lesion revascularization also show significant difference drug-coated stent ( 5.1 % ) bare metal stent ( 9.8 % ) ( P &lt; 0.001 ) . This result provide new therapeutic option DAPT duration could shorten 1 month patient high bleed risk . The rate cardiovascular event relatively high second generation DES . However , result carefully interpret main purpose LEADERS-FREE trial enroll high bleeding risk patient generally exclude second generation DES study . Additional study need limited clinical evidence extend finding LEADERS-FREE trial generalize patient eligible PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Subject â‰¥ 19 year Subject implant Biofreedom DCS within 1 month Subject decide participation sign informed consent Known intolerance heparin , aspirin , clopidogrel , biolimus , cobalt chromium contrast medium ( Subject hypersensitivity contrast medium control steroid pheniramine include study , subject anaphylaxis contrast medium exclude ) . Pregnancy Woman plan pregnancy study period Subject life expectancy le 12 month Subject cardiogenic shock Subject treat drugeluting stent ( DES ) , bioresorbable vascular scaffold ( BVS ) bare metal stent ( BMS ) Subject participate randomize control study DES , BVS BMS</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Observational registry</keyword>
	<keyword>All-comers open label registry</keyword>
	<keyword>Drug coat stent</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Stenting</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary revascularization</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>